<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PRAMLINTIDE</span><br/><span class="topboxtradename">Symlin<br/></span><b>Classifications:</b> <span class="classification">hormone &amp; synthetic substitute</span>; <span class="classification">antidiabetic agent</span>; <span class="classification">amylin analog</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.6 mg/mL solution for injection. Available as 5 mL vials</p>
<h1><a name="action">Actions</a></h1>
<p>Pramlintide is a synthetic analog of human amylin, a hormone secreted by pancreatic beta cells. In type 2 diabetic patients
         using insulin and in type 1 diabetics, beta cells in the pancreas are either damaged or destroyed, resulting in reduced secretion
         of both insulin and amylin after meals. Amylin reduces postmeal glucagon levels, thus lowering serum glucose level. 
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Pramlintide is an antihyperglycemic drug that controls postprandial blood glucose levels.</p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunct treatment of diabetes mellitus type 1 and type 2 in patients who use mealtime insulin therapy and who have failed
         to achieve desired glucose control despite optimal insulin therapy.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to pramlintide; noncompliance with insulin regime or medical care; HbA1C &gt;9%; hypoglycemia; gastroparesis;
         concomitant use of drugs to stimulate GI motility. Safety and efficacy in children not established. 
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Lactation, pregnancy (category C), alcohol.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Type 1 Diabetes Mellitus</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 15 mcg immediately before each major meal; may increase to 30 mcg, 45 mcg, and 60 mcg if no clinically significant nausea
               for 37 d. If nausea or vomiting persists at 45 mcg or 60 mcg, reduce to 30 mcg.<br/><br/><span class="indicationtitle">Type 2 Diabetes Mellitus</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 60 mcg immediately before each major meal; may increase to 120 mcg if no clinically significant nausea for 37 d. If nausea or vomiting persists at 120 mcg, reduce to 60 mcg.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>Give SC into the abdomen or thigh (not the arm) immediately before each major meal. Rotate injection sites.</li>
<li>Never mix pramlintide and insulin in the same syringe. Separate injection sites.</li>
<li>Use a U100 insulin syringe to administer. One Unit of pramlintide drawn from a 0.6 mg/mL vial contains 6 mcg of medication.
            Thus, a 30 mcg dose is equal to 5 U in a U100 syringe.
         </li>
<li>Do not administer to patients with HbA1c &gt;9% or those taking drugs to stimulate GI motility.</li>
<li>Note: When initiating pramlintide therapy, insulin dose reduction is required. </li>
<li>Store at 2°8° C (36°46° F), and protect from light. Do not freeze. Discard vials that have
            been frozen or overheated. Discard open vials after 28 d.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Dizziness, fatigue, <span class="speceff-common">headache</span>. <span class="typehead">GI:</span> Abdominal pain, <span class="speceff-common">anorexia,</span>
<span class="speceff-common">nausea, vomiting</span>. <span class="typehead">Musculoskeletal:</span> Arthralgia. <span class="typehead">Respiratory:</span>
<span class="speceff-common">Coughing,</span> pharyngitis.  <span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Allergic reaction,</span>
<span class="speceff-common">inflicted injury.</span>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drugs:</span> Pramlintide can decrease rate and/or extent of GI absorption of other oral drugs. Significant slowing of gastric motility
      with <span class="classification">antimuscarinics</span>.  
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 3040% bioavailability. <span class="typehead">Peak:</span> 20 min. <span class="typehead">Distribution:</span> 40% protein bound. <span class="typehead">Metabolism:</span> Extensive renal metabolism.  <span class="typehead">Half-Life:</span>  48 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for severe hypoglycemia, which usually occurs within 3 h of injection. Hypoglycemia is worse in type 1 diabetics.</li>
<li>Monitor diabetics for loss of glycemic control.</li>
<li>Lab tests: Baseline and periodic HbA1c; frequent pre/post meal plasma glucose levels. </li>
<li>Withhold drug and notify physician for clinically significant nausea or increased frequency or severity of hypoglycemia.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Follow directions for taking the drug (see Administration). Use a new needle for each injection.</li>
<li>Note: Patients should reduce a.c. rapid-acting or short-acting insulin dosages by 50% when pramlintide is initiated. Check
            with physician.
         </li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Report any of the following to physician: persistent, significant nausea; episodes of hypoglycemia (e.g., hunger, headache,
            sweating, tremor, irritability, or difficulty concentrating).
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>